<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979065</url>
  </required_header>
  <id_info>
    <org_study_id>NICO</org_study_id>
    <nct_id>NCT04979065</nct_id>
  </id_info>
  <brief_title>Nutrition, Immunity, and Covid-19 in Obese People</brief_title>
  <acronym>NICO</acronym>
  <official_title>Effect of Probiotic and Vitamin D Supplementation in Modulating Gut Dysbiosis, Nutrition, Inflammation and Immune Status and Reduce Risk of COVID-19 in Obese People: Gut-Lung Axis Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The increased risk of transmission of COVID-19 infection causes the incidence of death in&#xD;
      health workers to escalate. It requires further research on risk factors and intervention in&#xD;
      health worker professionals, especially on immunity factors and nutritional status. Quality&#xD;
      of diet and nutrition is very important to support the immune system when infected. Several&#xD;
      probiotic strains have been shown to decrease the duration and incidence of diarrhea and&#xD;
      respiratory infections, suggesting the Gut-Lung Axis pathway. Some probiotics also improve&#xD;
      the balance of diversity in the composition of the gut microbiota and affect body weight in&#xD;
      obese people. Probiotics have also been shown to improve vitamin D absorption. A combination&#xD;
      of vitamin D and probiotics may be an alternative to reduce gut dysbiosis that will directly&#xD;
      or indirectly reduce the risk and severity of viral infections including SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is increasing in Indonesia and is the cause of various diseases, especially in the&#xD;
      presence of Vitamin D deficiency, a state of dysbiosis, causing an increase in the&#xD;
      possibility of infection. Professional health workers have a high risk of COVID-19 due to&#xD;
      high daily exposure. Based on a review conducted by Daniel et al, it was found that 7.3% of&#xD;
      health workers at Reutters University tested positive for COVID-19. Based on data from the&#xD;
      Indonesian Doctors Association (IDI) on July 12, 2020, it was known that 61 doctors had died.&#xD;
      In addition, based on data from the Indonesian National Nurses Association (PPNI), 39 nurses&#xD;
      have died during the COVID-19 pandemic. Therefore efforts to prevent the occurrence of&#xD;
      COVID-19 infection by providing a combination of vitamin D and probiotics to modulate&#xD;
      dysbiosis that will further reduce the risk of viral infection, especially COVID-19, needs to&#xD;
      be investigated for its potential benefits.&#xD;
&#xD;
      Primary and secondary objectives&#xD;
&#xD;
        1. Primary Objective:&#xD;
&#xD;
           To investigate the effect of a combination of probiotics and vitamin D supplementation&#xD;
           in modulating intestinal dysbiosis, and vitamin D status, in people with overweight and&#xD;
           obesity, especially among frontline health workers.&#xD;
&#xD;
             -  To assess the mean changes in zonulin levels (as a parameter of gut integrity to&#xD;
                indicate the intestinal microbiota dysbiosis)&#xD;
&#xD;
             -  To assess the mean changes in serum vitamin D levels&#xD;
&#xD;
        2. Secondary Objectives:&#xD;
&#xD;
             -  To assess the relationship between nutritional status, inflammation and immunity&#xD;
                with the risk of COVID-19 infection in health workers.&#xD;
&#xD;
             -  To understand the difference in the mean episodes of Covid-19 infection between&#xD;
                treatment and placebo groups after giving probiotics and vitamin D in people with&#xD;
                overweight and obesity, especially among frontline health workers.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      This study has 2 phases Phase 1: a Cross-sectional study with 160 people Phase 2: a&#xD;
      double-blind, randomized, placebo-controlled trial with two arms of intervention involving a&#xD;
      total of 80 people.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 24, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Independent party will mask the product</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Zonulin level</measure>
    <time_frame>Baseline and endline (3 month)</time_frame>
    <description>To investigate the changes of Zonulin level during intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin D level</measure>
    <time_frame>Baseline and endline (3 month)</time_frame>
    <description>To investigate the changes of Vitamin D level during intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Baseline and endline (3 month)</time_frame>
    <description>Measurement of nutritional status using Body Mass Index (BMI) and waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota (optional)</measure>
    <time_frame>Baseline and endline (3 month)</time_frame>
    <description>Measurement of gut microbiota in fecal using Next Generation Sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation marker</measure>
    <time_frame>Screening</time_frame>
    <description>Measurement of inflammation markers IL-6, IL-10 TNF-Î± using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cathelicidin level</measure>
    <time_frame>Screening</time_frame>
    <description>Measurement of cathelicidin using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS COV-2</measure>
    <time_frame>Screening</time_frame>
    <description>Measurement of quantitative antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4/CD8 ratio</measure>
    <time_frame>Screening</time_frame>
    <description>Measurement of CD4/CD8 ratio using flowcytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covid-19 infection</measure>
    <time_frame>Baseline and endline (3 month)</time_frame>
    <description>Measurement of the reduction in risk of COVID-19 infection is seen from the difference in the average episodes between groups that were examined by PCR and/or Rapid antibody tests.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Covid19</condition>
  <condition>Overweight and Obesity</condition>
  <condition>Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotics and Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics, Vitamin D</intervention_name>
    <description>Combination of two supplement that given separately</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with inactive ingredient</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General doctors, specialist doctors, nurses and midwives who are in charge of handling&#xD;
             COVID-19 patients or working in COVID-19 referral hospitals for at least the last 3&#xD;
             months&#xD;
&#xD;
          -  20-65 years old&#xD;
&#xD;
          -  Willing to sign informed consent&#xD;
&#xD;
          -  Willing to follow the research to completion&#xD;
&#xD;
          -  BMI &gt; 23 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Have a confirmed history of COVID-19 based on previous PCR examinations&#xD;
&#xD;
          -  Suffering from acute illness known from history and physical examination or chronic&#xD;
             disease (eg diabetes, SLE, cardiovascular disease) known from history&#xD;
&#xD;
          -  Currently not on a diet program for weight loss or consuming probiotics regularly in&#xD;
             the last 3 months as known from the anamnesis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rina Agustina, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HNRC-IMERI, Faculty of Medicine Universitas Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rina Agustina, MD, PhD</last_name>
    <phone>+62213912477</phone>
    <email>dr.rinaagustina@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yani Kurniawan, MD, MM,</last_name>
    <phone>+62213912477</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Human Nutrition Research Center, Indonesian Medical Education Research Institute (HNRC-IMERI) Faculty of Medicine, Universitas Indonesia</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Rina Agustina</last_name>
      <phone>+6221 2912477</phone>
    </contact>
    <contact_backup>
      <last_name>Yani Kurniawan</last_name>
      <phone>+62213912477</phone>
      <email>hnrc.imeri@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rina Agustina, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erfi Prafiantini, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yani Kurniawan, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ari Fahrial Syam, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murdani Abdullah, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nurul Ratna Mutu Manikam, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Davrina Rianda, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanifa Hanifa, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natasha Dianasari Devana, dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chaula Putri Rizkia, dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, Li PH, Tan SY, Chang Q, Xie JP, Liu XQ, Xu J, Li DX, Yuen KY, Peiris, Guan Y. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003 Oct 25;362(9393):1353-8.</citation>
    <PMID>14585636</PMID>
  </reference>
  <reference>
    <citation>Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020 Mar 16;24:91-98. doi: 10.1016/j.jare.2020.03.005. eCollection 2020 Jul. Review.</citation>
    <PMID>32257431</PMID>
  </reference>
  <reference>
    <citation>Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation. 2020 Jul 7;142(1):4-6. doi: 10.1161/CIRCULATIONAHA.120.047659. Epub 2020 Apr 22.</citation>
    <PMID>32320270</PMID>
  </reference>
  <reference>
    <citation>Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. 2020 May 16;395(10236):1544-1545. doi: 10.1016/S0140-6736(20)31024-2. Epub 2020 May 4.</citation>
    <PMID>32380044</PMID>
  </reference>
  <reference>
    <citation>Nagpal R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. Obesity-Linked Gut Microbiome Dysbiosis Associated with Derangements in Gut Permeability and Intestinal Cellular Homeostasis Independent of Diet. J Diabetes Res. 2018 Sep 3;2018:3462092. doi: 10.1155/2018/3462092. eCollection 2018.</citation>
    <PMID>30250849</PMID>
  </reference>
  <reference>
    <citation>Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. Nutrients. 2020 Apr 23;12(4). pii: E1181. doi: 10.3390/nu12041181. Review.</citation>
    <PMID>32340216</PMID>
  </reference>
  <reference>
    <citation>Childs CE, Calder PC, Miles EA. Diet and Immune Function. Nutrients. 2019 Aug 16;11(8). pii: E1933. doi: 10.3390/nu11081933.</citation>
    <PMID>31426423</PMID>
  </reference>
  <reference>
    <citation>Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020 May;35(5):744-748. doi: 10.1111/jgh.15047. Epub 2020 Apr 19. Review.</citation>
    <PMID>32215956</PMID>
  </reference>
  <reference>
    <citation>King S, Glanville J, Sanders ME, Fitzgerald A, Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. Br J Nutr. 2014 Jul 14;112(1):41-54. doi: 10.1017/S0007114514000075. Epub 2014 Apr 29. Review.</citation>
    <PMID>24780623</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 24, 2021</last_update_submitted>
  <last_update_submitted_qc>July 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Rina Agustina</investigator_full_name>
    <investigator_title>Dr. dr. Rina Agustina, M.Gizi</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Immune status</keyword>
  <keyword>Covid-19</keyword>
  <keyword>Nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

